See the DrugPatentWatch profile for Amvuttra
Amvuttra received FDA approval on June 16, 2022 [1]. This approval was for the treatment of adult patients with transthyretin amyloidosis (ATTR amyloidosis) [1].
What is Amvuttra used to treat?
Amvuttra, also known by its generic name silencers, is approved for adults with transthyretin amyloidosis (ATTR amyloidosis) [1]. This condition affects both hereditary and wild-type forms of ATTR amyloidosis [1].
When does Amvuttra's patent protection expire?
Information regarding the specific patent expiry dates for Amvuttra is available through resources like DrugPatentWatch.com [2]. Patent and exclusivity information is crucial for understanding when generic versions of a drug might become available.
What are the side effects of Amvuttra?
Common side effects reported with Amvuttra include upper respiratory tract infections, pain in the extremities, and infusion-related reactions [1]. More serious potential side effects include kidney problems and liver problems [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How does Amvuttra work?
Amvuttra is a small interfering ribonucleic acid (siRNA) therapeutic that works by targeting and degrading the messenger RNA (mRNA) produced by the TTR gene [1]. This action reduces the production of transthyretin (TTR) protein, which is the underlying cause of ATTR amyloidosis [1]. By lowering TTR protein levels, Amvuttra aims to slow or halt the progression of the disease [1].
What clinical data supports Amvuttra's approval?
The FDA's approval of Amvuttra was based on data from a clinical trial demonstrating its efficacy in reducing serum TTR levels [1]. Specifically, the trial showed a significant reduction in TTR levels in patients treated with Amvuttra compared to placebo [1].
Who manufactures Amvuttra?
Amvuttra is manufactured by AstraZeneca [1].
What are the alternatives to Amvuttra for ATTR amyloidosis?
Other treatment options for ATTR amyloidosis include tafamidis (Vyndaqel/Vyndamax) and patisiran (Onpattro) [3]. Each medication has a different mechanism of action and may be suitable for different patient profiles.
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/amvuttra-tefr-ttr-treated-amyloid-neuropathy
[2] https://drugpatentwatch.com/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2113315